# US 2026/0117254 A1 · Compositions and methods for preparing viral vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0117254 A1
- Document ID: US20260117254A1
- Status: Published application
- Kind: A1
- Application number: 19/173,207
- Filed: 2025-04-08
- Published: 2026-04-30
- Earliest claimed: 2021-04-08
- Assignees: Nikegen Limited
- Applicants: Nikegen, LLC
- Inventors: Weidong XIAO; Xiangping YU
- Web page: https://patentgrep.com/patent/US20260117254A1

## CPC

- C12N 15/86: Viral vectors
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16051: Methods of production or purification of viral material
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14151: Methods of production or purification of viral material
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method for preparing an infectious, recombinant virus vector comprises the steps of: (a) infecting host cells with a first virus comprising an encapsidation defective adenovirus (edAd), the edAd comprising a first defective virus genome; (b) incubating the infected host cells in a culture medium for a period of time sufficient for producing infectious virus particles; and (c) recovering infectious virus particles secreted into a culture supernatant, wherein the edAd or the host cells comprise a second defective virus genome engineered to express a target gene of interest, wherein the edAd or the host cells comprise nucleic acid sequences sufficient for expressing adenovirus (Ad) helper genes necessary for replication of the defective virus DNA; and wherein the edAd or the host cells comprise nucleic acid sequences sufficient from expressing helper functions necessary for producing infectious, replication defective virus particles corresponding to the second virus.

## Claims

### Claim 1

An encapsidation defective adenovirus (edAd) for the production of a recombinant virus, comprising:
an edAd genome with one or more mutations that result in (1) significantly reduced production or non-production of one or more encapsidation essential proteins, and/or (2) the production of one or more defective encapsidation essential proteins.

### Claim 2 (depends on 1)

The edAd of claim 1, wherein the one or more encapsidation essential proteins are selected from the group consisting of capsid protein IX, encapsidation protein IVa2, protein 13.6, encapsidation protein 52K, capsid protein precursor pIIIa, penton base (capsid protein III), core protein precursor pVII, core protein V, core protein precursor pX, capsid protein precursor pVI, hexon (capsid protein II), protease, hexon assembly protein 100K, protein 33K, encapsidation protein 22K, capsid protein precursor pVIII, protein UXP, and fiber (capsid protein IV).

### Claim 3 (depends on 1)

The edAd of claim 1, wherein the one or more mutations comprise a mutation that results in the non-expression of capsid protein precursor pIIIa.

### Claim 4 (depends on 3)

The edAd of claim 3, further comprising one or more deletions in protein V, hexon, Iva2, L1-52/55k and/or L4-22K.

### Claim 5 (depends on 3)

The edAd of claim 3, further comprising a deletion in the fiber protein.

### Claim 6 (depends on 1)

The edAd of claim 1, wherein the one or more mutations comprise the deletion of hexon assembly protein 100K.

### Claim 7 (depends on 1)

The edAd of claim 1, further comprising one or more deletions in adenovirus early genes.

### Claim 8 (depends on 7)

The edAd of claim 7, comprising a deletion in adenovirus early gene E1.

### Claim 9 (depends on 7)

The edAd of claim 7, comprising a deletion in adenovirus early genes E1 and E3.

### Claim 10 (depends on 7)

The edAd of claim 7, comprising deletions in adenovirus early genes E1, E3 and E4.

### Claim 11 (depends on 1)

The edAd of claim 1, further comprising a sequence that encodes the genome of a recombinant AAV.

### Claim 12 (depends on 11)

The edAd of claim 11, wherein the genome of the recombinant AAV comprises an expression cassette comprising a target gene operably linked to a control sequence, wherein the expression cassette is flanked on each end with an AAV ITR.

### Claim 13 (depends on 1)

The edAd of claim 1, further comprising the coding sequence of CRE operatively linked to a control sequence.

### Claim 14 (depends on 1)

The edAd of claim 1, further comprising the coding sequence of the gag and pol proteins of a lentivirus.

### Claim 15 (depends on 1)

The edAd of claim 1, further comprising the coding sequence of the VSV-G protein of a lentivirus.

### Claim 16

A method for producing a recombinant virus (RV), comprising the steps of:
(a) infecting a producer cell with one or more edAds to produce an infected producer cell, wherein the one or more edAds are capable of DNA replication, but not virus particle formation, in the producer cell and wherein either the one or more edAds, or the producer cell, comprises a RV genome;
(b) incubating the infected producer cell under conditions that allow production of a RV having the RV genome; and
(c) harvesting the RV.

### Claim 17 (depends on 16)

The method of claim 16, wherein the RV is AAV.

### Claim 18 (depends on 17)

The method of claim 17, wherein the one or more edAds comprise an AAV genome.

### Claim 19 (depends on 1)

A packaging cell for producing the edAd of claim 1, wherein the packaging cell expresses one or more gene products that allow encapsidation of the edAd within the packaging cell.

### Claim 20 (depends on 19)

The packaging cell of claim 19, wherein the one or more gene products comprise adenovirus pIIIa gene product.
